China hospital has achieved complete remission in a lymphoma patient who relapsed after 5th-line chemotherapy through CAR-T cell therapy

Recently, a patient with relapsed lymphoma after 5th-line chemotherapy achieved complete remission for over two years through CAR-T therapy, marking one of the longest survivors following the approval of China’s first commercially available CAR-T treatment. This milestone was achieved by a team led by Professor Huang Huiqiang at Sun Yat-sen University Cancer Center.

Lymphoma is a common hematologic malignancy, traditionally treated with combined chemotherapy regimens, autologous hematopoietic stem cell transplantation, targeted therapy, and immunomodulatory agents. CAR-T (Chimeric Antigen Receptor T-cell) therapy, a cutting-edge precision oncology approach, has recently transitioned from experimental to clinical practice, offering rapid and highly effective treatment outcomes.

“Diffuse large B-cell lymphoma (DLBCL), a prevalent aggressive lymphoma, is characterized by rapid progression, high mortality, and short survival periods,” explained Huang Huiqiang. “While approximately 70% of patients achieve long-term disease-free survival through frontline therapies, about 30% face poor prognoses, relapse, or resistance to standard treatments. In such cases, CAR-T therapy emerges as a critical option, providing hope for patients ineligible for transplantation or unresponsive to prior therapies.”

Sun Yat-sen University Cancer Center plans to further explore innovative applications of CAR-T therapy in clinical research.

Chinese hospitals can now provide advanced CAR-T cell therapy technology for lymphoma, leukemia and other cancer patients around the world. The efficacy rate of China’s CAR-T cell technology is similar to that of the technology in the United States, but the price is only one-fourth of that in the US, or even lower. International patients can use the already marketed technology in China at a much lower cost than in the United States, or use the unmarketed technology at an even lower price, or participate in clinical trials for free. You can contact us at doctor.wang@globecancer.com for assistance in coming to China for treatment.